Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study analyzes surgical specimens from the SANO trial, revealing that local regrowth after neoadjuvant chemoradiotherapy predominantly involves mucosa and submucosa and supports endoscopic monitoring in active surveillance, with surger
The TC-MAX is the first validated, disease-specific instrument measuring thyroid cancer-related anxiety, showing strong reliability and validity to inform treatment decisions and improve patient-centered care.
In the SANO cohort, 85% of patients with uncertain post-chemoradiotherapy response had residual tumor at esophagectomy, supporting surgery for most, while highlighting a notable complete response subgroup among squamous cell carcinoma with
A prospective cohort study reveals that patients with low-risk papillary thyroid cancer experience similar quality of life outcomes at three years whether they choose active surveillance or immediate surgery, though those who crossover to s
A decision analytical model reveals that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy provides superior 5-year survival and quality-adjusted life-years (QALYs) for esophageal cancer patients a
A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for approp
A decision analytical model based on the SANO trial suggests that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy remains superior for maximizing long-term survival and quality-adjusted life-year
A comprehensive meta-analysis demonstrates that patients with papillary thyroid microcarcinoma managed via active surveillance experience significantly better health-related quality of life and fewer treatment-related symptoms than those un
The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression
A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.
Active surveillance is a durable management strategy for small, low-risk papillary thyroid cancer, especially among older adults who show significantly lower crossover rates to surgery.